Jerel is a Managing Director at Versant Venture Management, LLC, a healthcare investment firm. He has played a critical role in Versant’s company creation strategies and has been heavily involved in a number of public and private biotech companies such as Crispr (CRSP), BlueRock (sale), Repare (RPTX), Akero (AKRO), Graphite (GRPH), Chinook (KDKY), Inception 4 (sale), Inception 5 (sale), Northern (sale), Rayze, Ventus, Turnstone, and Tentarix. Prior to joining Versant, Jerel was an Associate Principal at McKinsey and Company where he advised healthcare corporations in pharmaceuticals, biotechnology, medical devices, and molecular diagnostics. He has worked in a number of healthcare markets globally, including the U.S., Europe, China, and Russia. Jerel earned his doctorate from Stanford University, where he also completed post-doctoral research.
Making progress and achieving milestones to create innovative medicines